GNF GAINS NOVEL INSIGHTS BY ANALYZING MULTIPLE BIOLOGICAL NETWORKS GENERATED BY IPA
Mountain View, California, November 24, 2003 - Ingenuity Systems announced today that the Genomics Institute of the Novartis Research Foundation (GNF) has licensed the IPA application for use in their research programs.
IPA is an innovative web-delivered application that enables biologists to discover, visualize, and explore therapeutically relevant networks significant to their experimental results. GNF’s evaluation of IPA particularly highlights the necessity of studying multiple biological networks underlying each experimental dataset to fully understand the biology of the experiment.
“The IPA application allowed us to immediately identify interesting biological insights in our gene expression data that we did not identify in many months of previous analysis. We’re looking forward to deploying this technology against further gene expression data, as well as in conjunction with our new siRNA screen technologies,” said John Hogenesch, senior research scientist at GNF.
Frank C. Mara, senior vice president of Ingenuity Systems stated, “Groundbreaking discovery happens when IPA is in the hands of world class researchers. We are excited to be working with such a prestigious research organization as GNF.”
About Ingenuity Systems
Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View, California.www.ingenuity.com.
About Genomics Institute of the Novartis Research Foundation (GNF)
The Genomics Institute of the Novartis Research Foundation (GNF) has integrated state of the art technologies, making possible new approaches to complex biomedical problems in the neurosciences, immunology and cancer biology. These technologies cut across the life sciences and include genomics and proteomics tools, combinatorial chemistry, structural genomics and computational biology. The mission of the Institute is to exploit these technologies to identify new biological processes and understand the underlying mechanisms involved in human disease. These discoveries are being translated into human therapeutics by a preclinical drug discovery effort. GNF was founded in 1999 and currently houses over 400 employees. The location of the 260,000 square foot research center is in the heart of the Torrey Pines Science Park. The Institute is funded through the Novartis Research Foundation which provides GNF the freedom to conduct independent research and allows many collaborative efforts with Novartis, other academic institutions and biotech facilities. For more information, go to www.gnf.org.